RBC Capital raised the firm’s price target on CG Oncology (CGON) to $61 from $53 and keeps an Outperform rating on the shares. CG Oncology’s Q3 update highlighted that its BLA filing is now underway, easing concerns about timing and keeping the company on track for a potentially strong non-muscle invasive bladder cancer launch with a more than $2.7B opportunity, the analyst tells investors in a research note. With additional Q4 catalysts ahead and a favorable safety/efficacy profile despite competitive questions, the outlook remains compelling, RBC says.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- CG Oncology, Inc.: Promising Future with Creto’s Accelerated Approval Path and Market Differentiation
- Strategic Advancements and Risk Mitigation Drive Buy Rating for CG Oncology, Inc.
- CG Oncology Advances Bladder Cancer Therapy Development
- CG Oncology Appoints Jim DeTore as Interim CFO
- CG Oncology’s Promising Developments and Competitive Edge Drive Buy Rating